Effective Cannabis | Research & Blog
In 2012, MS has been considered mainly an inflammatory disorder, recent evidence, however, revealed the importance of neurodegenerative events, opening the possibility to cannabinoid treatment. Mice were used BACKGROUND: Treatment with WIN55,512-2, a potent CB1 and CB2agonist, was reported to be effective to ameliorate tremor and spasticity in mice with chronic relapsing experimental autoimmune encephalomyelitis, You .. Read More
In 2019, THC (Dronabinol) has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. BACKGROUND: We have anecdotal evidence that THC may have contributed to disease control in a patient with acute undifferentiated leukemia. You can read the full article here => https://www.theroc.us/researchlibrary/Dronabinol%20has%20preferential%20antileukemic%20activity%20in%20acute%20lymphoblastic%20and%20myeloid%20leukemia%20with%20lymphoid%20differentiation%20patterns.pdf
In 2006, Δ9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria. BACKGROUND: investigated the molecular mechanisms underlying apoptosis induced by THC, specifically addressing the role of MAPK signaling. You can read the full article here => http://mcr.aacrjournals.org/content/4/8/549.long
in 2017, Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target BACKGROUND: Focus on the CB2 receptor as a promising pharmacological target in a number of neurodegenerative diseases. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288380/
In 2009, Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington’s disease BACKGROUND: Examined this hypothesis in a rat model of Huntington’s disease (HD) generated by intrastriatal injection of the mitochondrial complex II inhibitor malonate. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706932/
In 2013, Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma. BACKGROUND: Examined the distribution of CB1 protein in primary cases of HL. Using lymphoma derived cell lines. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857220/
In 2003, Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial BACKGROUND: Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid–protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways) You can read the full article here => https://www.researchgate.net/publication/10574358_Short-Term_Effects_of_Cannabinoids_in_Patients_with_HIV-1_Infection_A_Randomized_Placebo-Controlled_Clinical_Trial
In 2005, Cannabis Use in HIV for Pain and Other Medical Symptoms. HIV-positive individuals attending a large clinic were recruited into an anonymous cross-sectional questionnaire study. Patients completed the questionnaire while waiting and confidentiality was maintained by enumerating the papers without patient identification. You can read the full article here => 8http://www.jpsmjournal.com/article/S0885-3924(05)00063-1/fulltext
[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772142/ [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
In 2015, Glaucoma and the Benefits of Cannabis. Glaucoma is the result of a number of diseases that lead to the damage of the optic nerve. BACKGROUND: studies are on-going, but suggest that cannabis can be used as a protective treatment in addition to previously known benefits for treating glaucoma. You can read the full .. Read More
